셀라토즈테라퓨틱스셀라토즈테라퓨틱스
  • ABOUT US
    • ABOUT US
    • HISTORY
    • MISSION & VISIONS
    • CORPORATE STARATEGY
    • LEADERSHIP TEAM
    • SCIENTIFIC ADVISORY BOARD
  • OUR SCIENCES & PLATFORMS
    • OUR SCIENCES
    • A-to-Z CELLS
    • A-to-Z PLATFORMS
  • PIPELINES
    • OVERALL PIPELINES
  • CDMO
    • ABOUT CDMO
    • OBJECTIVE
    • GMP FACILITY
    • CDMO SERVICES
  • INVESTORS
    • PRESS RELEASE
    • EVENTS & PRESENTATIONS
    • INVESTMENT PARTNERS
  • CONTACT US
    • CONTACT INFO
    • PARTNERING
  • enEnglish
    • ko한국어

EVENTS & PRESENTATIONS

Cellatoz-ARM_Moment
Corporate Presentation at the 2021 Cell & Gene Meeting on the Mesa
2021.10.20
READ MORE L
Factsheet_Cellatoz Therapeutics, Inc._Oct 2021_페이지_1
Factsheet(Sept 2021)
2021.09.23
READ MORE L
CMT
Interview with CMT Research Foundation CEO
2021.07.20
READ MORE L
KoreaBIO
KoreaBio 2021 Global IR pitching @JPM
2021.07.20
READ MORE L
Cellatoz Therapeutics, Inc.
17, Pangyo-ro 228beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13487, Republic of Korea
TEL: +82-(0)31-622-4300 | FAX: +82-(0)31-622-4315 | E-mail: admin@cellatozrx.com
Copyright © CELLATOZ THERAPEUTICS, INC. All rights reserved.
Created by Presscat

Ho Jin Kim, MSc.

Senior Managing Director

Head of Research & Chief Technology Officer

Mr. Ho Jin Kim is head of Biology Research responsible for research and development of cell therapies at our company and has lots of experiences in cell culture with specialty in the process development of cell therapeutics. He served as a general manager and head of translation research team at CHABiotech R&D division and contributed to develop CHA Biotech’s extensive regenerative medicine pipelines. He is a member of Cell Therapy, International Society of Cell Therapy (ISCT), International Society for Stem Cell Research (ISSCR), and Asian Cell Therapy Organization (ACTO). He holds a bachelor’s and master’s degree and Ph.D diploma in biology from Soonchunhyang University.

Jaeseung Lim, Ph.D

Chief Executive Officer & Chief Science Officer

Educations

  • Post-Doctorial Fellow, OB/GY, Stanford University
  • Ph.D, Biochemistry & Molecular Biology, University of Leeds (UK)
  • MSc, Biochemistry, Chemistry Dept., Seoul National University
  • BS, Chemistry Dept., Seoul National University

Careers

  • Adjunctive Professor, Sookmyung Woman’s University
  • CEO & CSO, Cellatoz Therapeutics, Inc. (Korea)
  • CSO/Senior VP, CHA Biotech (Korea)
  • EVP, NexBio Corp. (Korea)
  • Co-founder & BoD memeber, MediCell Inc. (Korea, w/ KRIBB)
  • BoD member, Head of R&D, InnoCell Inc. (Korea)

Sunmin Hong, B.S.

Executive Director

Head of Development

Mr. Sunmin Hong is an expert in stem cell and cell therapy developments and build & operation of GMP facilities and he has involved in forging and registering at least 6 GMP facilities. He used to work for CHA Biotech, ATGen, NKBio and Boryung Pharmaceuticals etc spanning from pharma to cell therapy biotechs during his career.
He also worked as an inventor of NK cell therapy development as well. Mr. Hong earned a bachelor’s degree in biology from Dong-A University.

Sung-Chul Jung, MD, Ph.D

Professor of Department of Biochemistry

Dr. Sung-Chul Jung is a physician and a Professor of Department of Biochemistry, College of Medicine at Ewha Woman’s University and served as a director of Institute of Convergence Medicine at Ewha Woman’s University Medical Center. His research interests are therapeutic strategies (cell and gene therapies) for genetic diseases, molecular pathogenesis of inherited metabolic disease and sphingolipid metabolism and function on human health and disease. Dr. Jung and his research team have studied cell therapies using tonsil-derived MSC differentiated into Schwann cells and/or muscle cells.

Myung-Kwan Han, Ph.D

Professor of Department of Microbiology

Dr. Myung-Kwan Han is Professor of Department of Microbiology, School of Medicine at Chonbuk National University and served as a member of review board of National Research Foundation of Republic of Korea. He has been interested in studying regulation mechanisms of embryonic stem cell proliferation and differentiations as well as novel cellular functions of well-known molecules(e.g. insulin). He and his research team recently identified a novel ES-derived musculoskeletal stem cell with evident biological markers.

Akihiro Shimosaka, Ph.D

Chairperson, Asian Cellular Therapy Organization (ACTO)

Dr. Akihiro Shimosaka is a chairman of Asian Cellular Therapy Organization(ACTO) having served from 2010 and is a director of Research Foundation for Community Medicine in Japan. He is one of pioneer developing biotech business creating and operating Kirin-Amgen, a JV company between Kirin and Amgen for commercializing EPO, G-CSF and TPO in 1984. He had various positions and worked as business consultant in different companies including Genentech, Immunex, Dendreon, Anosys, Cerus, Miltenyi, Medarex etc. Furthermore, he has served as a chairman of International Society of Cell Therapy (ISCT) Regulatory Affairs.

Andy Byungho Song, MBA, MSc.

Vice President

Chief Financial Officer

Mr. Andy Byungho Song has more than 17 years of industry experiences in the business development and commercialization of novel therapeutics. He took various roles including Licensing, Marketing, New Brand launching , IP management, business planning and operating a subsidiary Indian company during his tenure at LG Life Sciences for 13 years, served as general manager and head of licensing team at CKD Pharm for 3 years, and then served as Vice President of operation & corporate development at Bridge Biotherapeutics, Inc., a Korean biotech company. He holds MBA degree from Korea University, master’s degree. in developmental biology from POSTECH and B.S in biology from Konkuk University.